Search results
Showing 136 to 150 of 381 results for depression
learning disabilities. This includes common mental health problems such as depression and anxiety disorders, or dementia in Down's...
Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B (TA96)
Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for treating chronic hepatitis B in adults.
Evidence-based recommendations on Alpha-Stim AID for managing anxiety disorders.
Evidence-based recommendations on endometrial cryotherapy for menorrhagia (heavy periods). This involves using cold temperatures to freeze and destroy the lining of the womb.
View recommendations for HTG101Show all sections
Sections for HTG101
Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance.
This guideline covers the planning and management of end of life and palliative care for infants, children and young people (aged 0 to 17 years) with life-limiting conditions. It aims to involve children, young people and their families in decisions about their care, and improve the support that is available to them throughout their lives.
Social, emotional and mental wellbeing in primary and secondary education (NG223)
This guideline covers ways to support social, emotional and mental wellbeing in children and young people in primary and secondary education (key stages 1 to 5), and people 25 years and under with special educational needs or disability in further education colleges. It aims to promote good social, emotional and psychological health to protect children and young people against behavioural and health problems.
of life. This may occur because of the direct impact of the anxiety or depression but also because of a negative interaction with the...
This guideline covers the identification, assessment and treatment of attachment difficulties in children and young people up to age 18 who are adopted from care, in special guardianship, looked after by local authorities in foster homes (including kinship foster care), residential settings and other accommodation, or on the edge of care. It aims to address the many emotional and psychological needs of children and young people in these situations, including those resulting from maltreatment.
Early value assessment (EVA) guidance on guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood.
Self-harm: assessment, management and preventing recurrence (NG225)
This guideline covers assessment, management and preventing recurrence for children, young people and adults who have self-harmed. It includes those with a mental health problem, neurodevelopmental disorder or learning disability and applies to all sectors that work with people who have self-harmed.
This guideline covers rehabilitation after stroke for over 16s. It aims to ensure people are assessed for common problems and conditions linked to stroke, and get the care and therapy they need. It includes recommendations on the organisation and delivery of rehabilitation in hospital and the community.
This quality standard covers identifying, assessing and treating attachment difficulties in children and young people (under 18). It focuses on children and young people at high risk of going into care, looked after by local authorities in foster homes, in special guardianship, adopted from care, and those in residential settings and other accommodation. It describes high-quality care in priority areas for improvement.
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)
Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.
Space from Depression for treating adults with depression (MIB215)
This advice has been updated and replaced by NICE HealthTech guidance 675.